Bajaj Healthcare Ltd (BAJAJHCARE) is currently trading at 338.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Bajaj Healthcare Limited is a major pharmaceutical manufacturer specializing in APIs, finished dosage forms, and nutraceuticals. It operates 20 state-of-the-art manufacturing facilities and exports products to over 60 countries. In FY 2025, Bajaj Healthcare achieved a total income of Rs 562.01 Cr, showcasing resilience amid challenging market conditions. The company maintains a net worth of Rs 486.39 Cr, illustrating a sound financial position. Bajaj Healthcare's strategic acquisition of Genrx Pharmaceuticals Private Limited marks a significant growth step, reinforcing its market presence and operational capacities. With a robust R&D pipeline, Bajaj Healthcare focuses on peptide synthesis and aims commercialization by March 2026, emphasizing its commitment to innovation and expanding global demand. Its CDMO partnership with UK/EU clients highlights Bajaj Healthcare's strategic move to enhance international collaborations, ensuring a foothold in lucrative markets and exclusive medicinal manufacturing.

Over the past 52 weeks, Bajaj Healthcare Ltd has traded between a low of ₹272.45 and a high of ₹516.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bajaj Healthcare Ltd has a market capitalization of approximately 1,107.67. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bajaj Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 48.10 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,107.67 Cr, Bajaj Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bajaj Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bajaj Healthcare Ltd is 48.10. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

It received a recommendation from the Subject Expert Committee (SEC) under CDSCO to manufacture and market Cenobamate tablets in six strengths.

The stock moved up after the company said the CDSCO’s Subject Expert Committee recommended approval to manufacture and market Cenobamate tablets.

The SEC (Neurology and Psychiatry) under CDSCO recommended that Bajaj Healthcare conduct Phase III clinical trials for Suvorexant tablets.

The record date stated in the Letter of Offer is Friday, September 5, 2025.